Audiology Clinic | |
845 N Limestone St, Gaffney, SC 29340-2512 | |
(864) 487-7207 | |
Not Available |
Full Name | Audiology Clinic |
---|---|
Type | Facility |
Speciality | Audiologist |
Location | 845 N Limestone St, Gaffney, South Carolina |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1083967665 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
231H00000X | Audiologist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Audiology Clinic 845 N Limestone St, Po Box 369, Gaffney, SC 29340-2512 Ph: () - | Audiology Clinic 845 N Limestone St, Gaffney, SC 29340-2512 Ph: (864) 487-7207 |
News Archive
Scientists at Joslin Diabetes Center, Harvard University, and the University of Cambridge have found that the age-related impairment of the body's ability to replace protective myelin sheaths, which normally surround nerve fibers and allow them to send signals properly, may be reversible, offering new hope that therapeutic strategies aimed at restoring efficient regeneration can be effective in the central nervous system throughout life.
"There were more than 275,000 cases in the U.S. last year of medical information theft, twice the number in 2008, according to Javelin Strategy & Research, a Pleasanton, California-based market research firm.
Bolder BioTechnology, Inc. today announced that it has been awarded a $1.9 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health (NIH).
A new report released today by the National Pharmaceutical Council (NPC) provides guidance in the evaluation of comparative effectiveness research (CER), including easy-to-use "checklists" that help make sure such studies can be used to improve the dialogue between health care providers and patients, as well as better inform health care decision-making.
Protalix BioTherapeutics, Inc.,a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell based expression system, today announced that the Company's common stock has been approved for listing on the Tel Aviv Stock Exchange in addition to its current listing on the NYSE Amex.
› Verified 1 days ago